LSD1 represses a myeloid-specific enhancer of the CEBPA gene via H3K4 demethylation. (A) Top 10 upregulated genes by LSD1 inhibition. Fold change (FC) values relative to untreated control are indicated. (B) Expression of C/EBPα protein in LSD1-KD– and S2101-treated HEL cells. (C-D) Expression changes of myeloid-related genes in LSD1-KD– and S2101-treated HEL cells. (E) Enrichment of H3K4me1, H3K4me2, and LSD1 at the CEBPA gene locus by ChIP-sequencing analysis. LSD1-KD data are also indicated. Red line indicates the ChIP-qPCR primer at the myeloid-specific enhancer. Data were visualized by using Integrative Genomics Viewer (http://software.broadinstitute.org/software/igv/). (F) Increase of H3K4me1, H3K4me2, and H3K27ac at the CEBPA enhancer by LSD1-KD. ChIP-qPCR signals were calculated relative to that of histone H3. (G) Enrichment of LSD1 at CEBPA enhancer examined by ChIP-qPCR. (H) Enrichment of GATA1 at theCEBPA enhancer in HEL cells tested by ChIP-qPCR. Enrichment values at the enhancer were normalized to input DNAs for panels F to H. (I) Upregulation of CEBPA in GATA1-KD HEL cells. Values are mean ± standard deviation of triplicate results. *P < .05, **P < .01.